Socioeconomic factors and SGLT2 inhibitor initiation in patients with heart failure—a claims data analysis
-
By
-
Lisa–Marie Müller
-
Jonas Krampe
-
Julius L. Katzmann
-
Ulrich Laufs
-
Alexander Kogel
-
July 7, 2026
-
Clinical Scorecard: Impact of Socioeconomic Status on the Initiation of SGLT2 Inhibitors in Heart Failure Patients: An Analysis of Claims Data
At a Glance
| Category | Detail |
|---|
| Condition | Heart Failure |
| Key Mechanisms | SGLT2 inhibitors reduce cardiovascular death and hospitalisation for heart failure. |
| Target Population | Patients with chronic heart failure and full insurance coverage. |
| Care Setting | Real-world prescription patterns analysis |
Key Highlights
- Socioeconomic factors influence the initiation of SGLT2 inhibitors in heart failure patients.
- SGLT2 inhibitors are recommended for all heart failure patients regardless of ejection fraction.
- Disparities in prescription rates may exist based on socioeconomic status and gender.
Guideline-Based Recommendations
Diagnosis
- ICD–10–GM codes for heart failure: I50.1 (left ventricular failure) and I50.9 (unspecified heart failure).
Management
- SGLT2 inhibitors should be initiated in heart failure patients.
Monitoring & Follow-up
- Assess patient demographics and socioeconomic factors influencing treatment initiation.
Risks
- Contraindications for SGLT2 inhibitors include chronic kidney disease stage 5 and type 1 diabetes.
Patient & Prescribing Data
Individuals with heart failure and full insurance coverage in 2022 and 2023.
SGLT2 inhibitors include dapagliflozin and empagliflozin.
Clinical Best Practices
- Utilize claims data to identify disparities in medication initiation.
- Consider socioeconomic factors when prescribing SGLT2 inhibitors.
Related Resources & Content
